METHODS: We retrospectively reviewed medical records of 423 breast or ovarian cancer patients who underwent BRCA1/2 genetic testing from 2010 to 2017. The VUSs in BRCA1/2 were reanalyzed using the 2015 American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines (ACMG/AMP 2015 guidelines) and the VUS was reclassified into five categories: \"pathogenic\", \"likely pathogenic\", \"VUS\", \"likely benign\", and \"benign\".
RESULTS: A total of 75 patients (48 sequence types of VUS) were identified as carrying either one or more VUS in BRCA1/2. Among the 75 patients, two patients (2.7%) were reclassified as \"likely pathogenic\", 30 patients (40.0%) were reclassified as either \"benign\" or \"likely benign\", and the remaining 43 patients (57.3%) were still classified as VUS category.
CONCLUSIONS: Since the clinical significance of VUS in BRCA1/2 may vary from time to time, reinterpretation of the VUS results could contribute to clinical decision-making.